^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tri-Ad5

    i
    Other names: Tri-Ad5, Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Ad5-CEA/Ad5-MUC1/Ad5-Brachyury Vaccine Tri-Ad5, Adenoviral CEA/MUC1/Brachyury Vaccine Tri-Ad5
    Associations

    News

    Trials
    Company:
    ImmunityBio, National Cancer Institute - Bethesda
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    4ms
    Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (clinicaltrials.gov)
    P2, N=186, Recruiting, National Cancer Institute (NCI) | Phase classification: P2b --> P2
    Phase classification
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • EPCAM (Epithelial cell adhesion molecule)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5
    1year
    Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (clinicaltrials.gov)
    P2b, N=186, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Initiation date: Aug 2023 --> Mar 2023
    Enrollment open • Trial initiation date
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • EPCAM (Epithelial cell adhesion molecule)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5
    1year
    Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (clinicaltrials.gov)
    P2b, N=186, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2026 --> Feb 2027 | Initiation date: Nov 2022 --> Aug 2023 | Trial primary completion date: Oct 2026 --> Feb 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • EPCAM (Epithelial cell adhesion molecule)
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5